+

e a plus sign (+) inside this box →

OCT 1 5 2004

**DT03 Red** 

CT/PTO

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	10/502,145			
		Filing Date	Not Yet Assigned			
TRANSMITTAL	-	First Named Inventor	MACKAY, CHARLES REAY			
FORM		Group Art Unit	Not Yet Assigned			
(to be used for all correspondence after initi	ial filing)	Examiner Name	Not Yet Assigned			
Total Number of Pages in This Submissio	on 3	Attorney Docket Number	RICE-032			
		ES (check all that apply)				
Fee Transmittal Form Fee Attached Amendment / Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement SB08a Form Certified Copy of Priority Documents Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Assign (for an Drawin Licens Petitio Provis Power Chang Addres Termin Reque	iment Papers Application) ing(s) ing-related Papers in in to Convert to a ional Application of Attorney, Revocation is of Correspondence	After Allowance Communication to Group Appeal Communication to Board of Appeals and Interferences  Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter  Other Enclosure(s) (please identify below): 10 References Postcard			
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Signing Attorney/Agent (Reg. No.)  Signature  CARØI) L. FRANCIS, 36,513 BOZICEVIC, FIELD & FRANCIS, LLP  Date  October 15, 2004						

EXPRESS MAIL LABEL NO. 519866440 US

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.





## INFORMATION DISCLOSURE STATEMENT

Attorney Docket RICE-032

First Named Inventor MACKAY, CHARLES REAY

Application Number 10/502,145

Confirmation No. Not Yet Assigned

Filing Date Not Yet Assigned

Group Art Unit Not Yet Assigned

Examiner Name Not Yet Assigned

Title: "MONOCLONAL ANTIBODIES AGAINST

Address to: Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

"MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR"

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-SB/08A listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewednd made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C.§102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815, Order No. RICE-032 may be charged thereon.

Respectfully submitted,

**BOZICEVIC, FIELD & FRANCIS LLP** 

BOZICEVIC, FIELD & FRANCIS LLP

1900 University Avenue, Suite 200 East Palo Alto, California 94303

Telephone: (650) 327-3400 Facsimile: (650) 327-3231

Carol L. Francis/ Registration No. 26,513 OCT 15 2004 SEE

PTO/SB/08a (05-03)
PTO/SB/08a (05-03)
PTO/SB/08a (05-03)
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known Substitute for form 1449A/PTO **Application Number** 10/502,145 **INFORMATION DISCLOSURE** Not yet assigned Filing Date STATEMENT BY APPLICANT First Named Inventor MACKAY, CHARLES REAY Art Unit Not yet assigned **Examiner Name** (use as many sheets as necessary) Not yet assigned Sheet 1 Attorney Docket Number RICE-032 1

			U.S. PATENT	OCUMENTS		
Examiner Initials'	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
		Number-Kind Code <sup>2</sup> (if known) US-		Applicant of Cited Document		
		US-				

FOREIGN PATENT DOCUMENTS						
Examiner Initials'	Cite No.1	Foreign Patent Document  Country Code <sup>3</sup> –Number <sup>4</sup> –Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁵
		EP 0 377 489	07/11/1990	Merck & Co. Inc.		
		WO 95/00164	01/05/1995	The Scripps Research Institute		

		OTHER ART—NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1  Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
		Elsner, et al., "C3a activates the respiratory burst in human polymorphonuclear neutrophilic leukocytes via pertussis toxinsensitive g-proteins", Blood, (1994), vol. 83, no. 11, pp. 33224-3331		
		Farkas et al., "C5a receptor expression by TGW neuroblastoma cells", NeuroReport (1999), vol. 10, no. 14, pgs. 3021-3025.		
		Fayyazi et al., "The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells", Immunology, (2000), vol. 99, no. 1, pgs. 3845.		
		Jagels, et al., "Proteolytic inactivation of the leukocyte C5a receptor by proteinases derived from porphyromonas gingivalis", Infection and Immunity, (1996), vol. 64, no. 6, pgs. 19841991.		
		Oppermann, et al., "Probing the human receptor for C5a anaphylatoxin with site-directed antibodies", The Journal of Immunology, (1993) vol. 151, no. 7, pg. 3785-3794.		
		Schlaf, et al., "Differential expression of the C5a receptor on the main cell types of rat liver as demonstrated with a novel monoclonal antibody and by C5a anaphylatoxin-induced Ca <sup>2+</sup> release", Laboratory Investigation, (1999) vol. 79, no. 10, pgs. 1287-1297.		
		Sayah, et al., "Expression of cytokines by human astrocytomas following stimulation by C3a anaphylatorxins: specific increase in interleukin-6 mRNA expression", Journal of Neurochemistry (1999), col. 72, no. 6, pgs. 24262436.		
		Watanabe, et al., "Analysis of C5a receptor by monoclonal antibody, Journal of Immunological Methods, (1995), vol. 185, no. 1, pgs. 19-29.		

Examiner	Date	
Signature	 Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**DATE: October 15, 2004** 

## THE EXPRESS MALL NUMBER OF THE DAY IS: EV519266440US The person taking the Expense Mail to the Post Office is: Stua

OCT 1 5 2004

EXPRESS MAIL CERTIFICATION

Date of Deposit: 10/15/2004 I hereby certify that the below-listed papers or fees were inserted into a package addressed to: Commissioner for Patents, PO BOX 1450, Alexandria, Virginia 22313-1450 and was deposited by me with the United States Postal Express Mail Post Office Addressee" service under 37 C.F.R. § 1.10 on the date indicated above.

PEV519866440US

Atty. Docket No.	Serial Number	Description	Atty.	Fee
LIFE-080CON	10/278,170	Request for RCE Transmittal, Fee Sheet in duplicate, IDS, SB08A, (1) Cited Reference w/English Translation	CML	\$790
LIFE-034	10/013,856	Request for RCE Transmittal, Fee Sheet in duplicate, Amendment After Final Rejection, IDS, SB08A, Copy of SG Search Report (AU), (2) Cited References	CML	\$790
EPIT-007	10/869,355	Transmittal, Fee Sheet in duplicate, Executed Declaration, Copy of Notice to File Missing Parts, IDS, SB08A, (1) Cited References	JSK	\$65
UCSF-084CON2	10/915,017	Transmittal, Preliminary Amendment	PAB	
UCAL-161DIV	09/922,483	Transmittal, Notice of Appeal in duplicate (w/Petition for a 3 Month Extension)	PAB	\$660
REDL-008	10/882,993	Transmittal, Form 2038, Copy of Notice to File Missing Parts, Executed Declaration	BEF	\$460
CELL-003	08/182,247	Withdraw of POA w/Supporting Documents	PJS	
CELL-003CIP	08/380,916	Withdraw of POA w/Supporting Documents	PJS	
CELL-003CIP2	08/721,690	Withdraw of POA w/Supporting Documents	PJS	
CELL-003CON	08/891,581	Withdraw of POA w/Supporting Documents	PJS	W
CELL-004	08/495,034	Withdraw of POA w/Supporting Documents	PJS	
CELL-004CIP	08/669,753	Withdraw of POA w/Supporting Documents	PJS	
CELL-004CIP3	10/139,089	Withdraw of POA w/Supporting Documents	PJS	
CELL-014	09/392,822	Withdraw of POA w/Supporting Documents	PJS	
CELL-013	09/413,044	Withdraw of POA w/Supporting Documents	PJS	
GTIN-004	10/081,969	Withdraw of POA w/Supporting Documents	PJS	
GTIN-003	10/602,853	Withdraw of POA w/Supporting Documents	PJS	
CELL-030PRV	60/556,549	Withdraw of POA w/Supporting Documents	PJS	
GTIN-012CON	10/816,726	Withdraw of POA w/Supporting Documents	PJS	
CELL-031PRV	60/601,103	Withdraw of POA w/Supporting Documents	PJS	
CELL-002	10/183,972	Withdraw of POA w/Supporting Documents	PJS	
CELL-011CON	09/875,228	Withdraw of POA w/Supporting Documents	PJS	
CELL-006	09/033,428	Withdraw of POA w/Supporting Documents	PJS	
CELL-005CIP	08/906,192	Withdraw of POA w/Supporting Documents	PJS	
CELL-009CON .	09/614,495	Withdraw of POA w/Supporting Documents	PJS	
CELL-009	09/033,333	Withdraw of POA w/Supporting Documents	PJS	
CELL-007CON	10/045,116	Withdraw of POA w/Supporting Documents	PJS	
CELL-005	08/692,759	Withdraw of POA w/Supporting Documents	PJS	
GTIN-005	10/081,961	Transmittal, Restriction Election, Withdraw of POA w/Supporting Documents	PJS	
CELL-004CON	09/732,169	Withdraw of POA w/Supporting Documents	PJS	
CELL-006CON2	09/898,883	Withdraw of POA w/Supporting Documents	PJS	
CELL-009CON2	10/222,479	Withdraw of POA w/Supporting Documents	PJS	
CELL-006CIP	09/509,591	Withdraw of POA w/Supporting Documents	PJS	
CELL-012	09/033,556	Withdraw of POA w/Supporting Documents	PJS	T
CELL-015	09/474,699	Withdraw of POA w/Supporting Documents	PJS	
CELL-015CON	10/226,820	Withdraw of POA w/Supporting Documents	PJS	
CELL-016	- 09/814,292	Withdraw of POA w/Supporting Documents	PJS	
UCAL-223CIP4	10/133,289	Petition for a 1 Month Extension of Time in duplicate	CLF	\$55
RICE-032	10/502,145	Transmittal, IDS, SB08A, (10) Cited References	CLF	